Group One Trading
HRTX icon

Group One Trading’s Heron Therapeutics HRTX Stock Holding History

Group One Trading’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,700
Closed -$12.2K – 8560
2025
Q3 		$12.2K Buy
9,700
+4,700
+94% +$7.45K ﹤0.01% 7051
2025
Q2 		$10.3K Sell
5,000
-5,400
-52% -$11K ﹤0.01% 6695
2025
Q1 		$22.9K Buy
10,400
+10,100
+3,367% +$19.6K ﹤0.01% 5734
2024
Q4 		$459 Sell
300
-2,600
-90% -$4.21K ﹤0.01% 7010
2024
Q3 		$5.77K Sell
2,900
-50,000
-95% -$119K ﹤0.01% 5822
2024
Q2 		$185K Buy
52,900
+50,900
+2,545% +$156K ﹤0.01% 3459
2024
Q1 		$5.54K Sell
2,000
-300
-13% -$754 ﹤0.01% 6144
2023
Q4 		$3.91K Sell
2,300
-6,900
-75% -$7.6K ﹤0.01% 6604
2023
Q3 		$9.48K Buy
+9,200
New +$13.1K ﹤0.01% 6364
2023
Q2 		– Sell
-23,800
Closed -$35.9K – 7895
2023
Q1 		$35.9K Buy
+23,800
New +$59.6K ﹤0.01% 5103
2022
Q4 		– Sell
-800
Closed -$3K – 7599
2022
Q3 		$3K Buy
800
+600
+300% +$2.35K ﹤0.01% 7018
2022
Q2 		$1K Sell
200
-9,500
-98% -$38.1K ﹤0.01% 7549
2022
Q1 		$55K Sell
9,700
-4,100
-30% -$30K ﹤0.01% 6019
2021
Q4 		$126K Buy
13,800
+1,900
+16% +$19.4K ﹤0.01% 5516
2021
Q3 		$127K Sell
11,900
-21,700
-65% -$264K ﹤0.01% 5666
2021
Q2 		$521K Buy
33,600
+21,000
+167% +$334K ﹤0.01% 4182
2021
Q1 		$204K Buy
12,600
+2,600
+26% +$46.4K ﹤0.01% 5009
2020
Q4 		$212K Sell
10,000
-7,000
-41% -$122K ﹤0.01% 4016
2020
Q3 		$252K Sell
17,000
-67,100
-80% -$1.05M ﹤0.01% 3471
2020
Q2 		$1.24M Buy
84,100
+9,800
+13% +$161K 0.01% 1835
2020
Q1 		$872K Buy
74,300
+63,100
+563% +$1.19M 0.01% 1625
2019
Q4 		$263K Sell
11,200
-11,900
-52% -$263K ﹤0.01% 2964
2019
Q3 		$427K Buy
23,100
+10,700
+86% +$197K ﹤0.01% 2464
2019
Q2 		$231K Hold
12,400
– – ﹤0.01% 2745
2019
Q1 		$303K Buy
12,400
+3,500
+39% +$91.6K ﹤0.01% 2372
2018
Q4 		$231K Sell
8,900
-10,100
-53% -$278K ﹤0.01% 2574
2018
Q3 		$601K Sell
19,000
-95,000
-83% -$3.54M ﹤0.01% 2137
2018
Q2 		$4.43M Buy
114,000
+5,400
+5% +$172K 0.04% 612
2018
Q1 		$3M Buy
108,600
+59,000
+119% +$1.34M 0.03% 737
2017
Q4 		$898K Buy
49,600
+47,400
+2,155% +$773K 0.01% 1802
2017
Q3 		$36K Sell
2,200
-4,500
-67% -$70.6K ﹤0.01% 3792
2017
Q2 		$93K Sell
6,700
-7,200
-52% -$104K ﹤0.01% 3160
2017
Q1 		$209K Sell
13,900
-42,700
-75% -$591K ﹤0.01% 2495
2016
Q4 		$741K Buy
56,600
+43,400
+329% +$681K 0.01% 1513
2016
Q3 		$227K Sell
13,200
-142,000
-91% -$2.63M ﹤0.01% 2385
2016
Q2 		$2.8M Buy
155,200
+117,700
+314% +$2.3M 0.03% 629
2016
Q1 		$712K Buy
37,500
+34,500
+1,150% +$681K 0.01% 1437
2015
Q4 		$80K Sell
3,000
-349,700
-99% -$9.35M ﹤0.01% 3128
2015
Q3 		$8.61M Buy
352,700
+229,500
+186% +$7.65M 0.12% 183
2015
Q2 		$3.84M Buy
123,200
+115,400
+1,479% +$2.17M 0.05% 424
2015
Q1 		$113K Buy
+7,800
New +$87.9K ﹤0.01% 2824
2014
Q4 		– Sell
-1,000
Closed -$8K – 5058
2014
Q3 		$8K Hold
1,000
– – ﹤0.01% 4561
2014
Q2 		$12K Buy
+1,000
New +$11.9K ﹤0.01% 4447

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Group One Trading's HRTX Position: Q1 2026 in Review

Group One Trading reduced its Heron Therapeutics (HRTX) stake by 40% in Q1 2026, selling an estimated $67.6K and leaving 86,809 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5015.

Group One Trading first reported a position in HRTX in Q2 2014 and has held it in 32 quarters since. The position peaked at $6.15M in Q3 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Group One Trading held 86,809 shares of Heron Therapeutics worth $69.5K as of Q1 2026.
  • Group One Trading sold 58,358 Heron Therapeutics shares in Q1 2026, an estimated $67.6K.
  • Heron Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5015 holding.
  • Group One Trading first reported a position in Heron Therapeutics in Q2 2014 and has held it in 32 quarters since.
  • Group One Trading's Heron Therapeutics position peaked at $6.15M in Q3 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.